Kizaki, Masahiro
,
Takahashi, Naoto http://orcid.org/0000-0002-6758-3787
Iriyama, Noriyoshi
Okamoto, Shinichiro
Ono, Takaaki
Usui, Noriko
Inokuchi, Koiti
Nakaseko, Chiaki
Kurokawa, Mineo
Sumi, Masahiko
Nakamura, Fumihiko
Kawaguchi, Tatsuya
Suzuki, Ritsuro
Yamamoto, Kazuhito
Ohnishi, Kazunori
Matsumura, Itaru
Naoe, Tomoki
Article History
Received: 29 January 2019
Revised: 5 February 2019
Accepted: 6 February 2019
First Online: 14 February 2019
Compliance with ethical standards
:
: M. Kizaki reports personal fees from Bristol-Myers Squibb, Celgene, Nippon Shinyaku, Takeda Pharmaceutical, and Ono Pharmaceutical, and grants from Kyowa Hakko Kirin, Chugai Pharmaceutical, and Pfizer, outside the submitted work; N. Takahashi reports grants and personal fees from Novartis Pharmaceuticals, Pfizer, and Otsuka Pharmaceutical, personal fees from Bristol-Myers Squibb, and grants from Kyowa Hakko Kirin, Astellas Pharma, Chugai Pharmaceutical, Asahi Kasei Pharma, Ono Pharmaceutical, and Eisai Pharmaceuticals, outside the submitted work; S. Okamoto reports grants and personal fees from Otsuka Pharmaceutical, Novartis Pharmaceuticals, Bristol-Meyer Squib, Astellas Pharma, Kyowa Hakko Kirin, and Chugai Pharmaceutical, and personal fees from Pfizer, outside the submitted work; T. Ono reports grants from Celgene, Kyowa Hakko Kirin, Chugai Pharmaceutical, and Merck Sharp & Dohme, and personal fees from Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceutical, outside the submitted work; N. Usui reports personal fees from AbbVie Inc., Astellas Pharma, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CIMIC, Huya Bioscience International, Kyowa Hakko Kirin, Nippon Shinyaku Pharmaceutical, Daiichi Sankyo, Otsuka Pharmaceutical, Pfizer, SymBio Pharmaceuticals, Sysmex, Takeda Pharmaceutical, Takara Bio Inc., Sumitomo Dainippon Pharma, Zenyaku Kogyo, Alexion Pharmaceuticals, Taisho Toyama Pharmaceutical, Mochida Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical, and Meiji Seika Pharma, outside the submitted work; K. Inokuchi reports grants and personal fees from Bristol-Myers Squibb, personal fees from Novartis Pharmaceuticals, Celgene, and Pfizer, outside the submitted work; C. Nakaseko reports grants and personal fees from Pfizer, grants from Kyowa Hakko Kirin, Daiichi Sankyo, Astellas Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, and Chugai Pharmaceutical, personal fees from Novartis Pharmaceuticals, and Celgene, outside the submitted work; M. Kurokawa reports grants from Novartis Pharmaceuticals, Bristol-Meyer Squib, Astellas Pharma, Kyowa Hakko Kirin, Pfizer, Takeda Pharmaceutical, Ono Pharmaceutical, and Nippon Shinyaku Pharmaceutical, and personal fees from Celgene, and Shionogi, outside the submitted work; T. Kawaguchi reports grants and personal fees from MSD, and personal fees from Pfizer, Alexion Pharma, and Novartis Pharmaceuticals, outside the submitted work; R. Suzuki reports personal fees from Bristol-Meyer Squib, Novartis Pharmaceuticals, Kyowa-Hakko Kirin, Chugai Pharmaceutical, Shionogi, Takeda Pharmaceutical, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Sawai, Celgene, Sumitomo Dainippon Pharma, Eisai Pharmaceuticals, Alexion Pharma, Sanofi, Gilead Sciences, Abbvie Inc., Mundi Pharma, Jazz Pharma, Ono Pharmaceutical, and Janssen Pharmaceuticals, outside the submitted work; K. Yamamoto reports grants and personal fees from Astra-Zeneca, Celgene, Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Novartis Pharmaceuticals, Ono Pharmaceutical, Takeda Pharmaceutical, and Zenyaku, and grants from AbbVie Inc., ARIAD, Bayer, Gilead Sciences, Solasia Pharma, and SymBio, and personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida, Mundipharma, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and Boehringer Ingelheim, outside the submitted work; I. Matsumura reports grants and personal fees from Bristol-Myers Squibb, Novartis Pharmaceuticals, during the conduct of the study, grants and personal fees from Nippon Shinyaku Pharmaceutical, Celgene, Pfizer, Otsuka Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Shionogi, and Teijin Pharma, personal fees from Janssen Pharmaceutical, Boehringer Ingelheim, Sanofi, grants from Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Asahi Kasei Pharma, Astellas Pharma, Takeda Pharmaceutical, Japan Blood Products Organization, Nihon Pharmaceutical, and Daiichi Sankyo, outside the submitted work; the other authors have nothing to disclose.